Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
EOLS Stock Chart & Stats
$4.66
-$0.47(-4.38%)
At close: 4:00 PM EST
$4.66
-$0.47(-4.38%)
Day’s Range― - ―
52-Week Range$4.56 - $17.12
Previous CloseN/A
Volume344.54K
Average Volume (3M)1.20M
Market Cap
$304.00M
Enterprise Value$415.37M
Total Cash (Recent Filing)$43.52M
Total Debt (Recent Filing)$154.89M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Mar 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding64,819,786
10 Day Avg. Volume1,278,493
30 Day Avg. Volume1,196,949
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)123.99
Price to Sales (P/S)2.57
P/FCF Ratio-35.16
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue1.45
Enterprise Value/Gross Profit2.21
Enterprise Value/Ebitda-14.17
Forecast
1Y Price Target
$17.25Price Target Upside270.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial FlexibilityHealthy cash reserves and access to debt facilities without restrictive covenants provide flexibility to fund commercialization and manage through market softness.
Market Share And Competitive PositioningStrengthened positioning for Jeuveau and indications of market share gains suggest potential outperformance versus peers as demand recovers.
Product Portfolio ExpansionCommercial rollout of new Evolysse injectable fillers should diversify revenue and strengthen the company's aesthetic portfolio, reducing reliance on a single product line.
Bears Say
Guidance Overhang And Investor UncertaintyAn ambitious multiyear revenue target is acting as an overhang, increasing investor skepticism and amplifying downside risk if execution falls short.
Macro And Consumer Spending HeadwindsOngoing macroeconomic pressures and weak consumer sentiment are constraining discretionary spending on aesthetic treatments, pressuring toxin and filler sales.
Reduced Long-term OutlookA material downward revision to the long-term revenue outlook lowers growth expectations and raises questions about the company's ability to meet prior ambitions.
Evolus News
EOLS FAQ
What was Evolus Inc’s price range in the past 12 months?
Evolus Inc lowest stock price was $4.56 and its highest was $17.12 in the past 12 months.
What is Evolus Inc’s market cap?
Evolus Inc’s market cap is $304.00M.
When is Evolus Inc’s upcoming earnings report date?
Evolus Inc’s upcoming earnings report date is Mar 11, 2026 which is in 39 days.
How were Evolus Inc’s earnings last quarter?
Evolus Inc released its earnings results on Nov 05, 2025. The company reported -$0.132 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.031.
Is Evolus Inc overvalued?
According to Wall Street analysts Evolus Inc’s price is currently Undervalued.
Does Evolus Inc pay dividends?
Evolus Inc does not currently pay dividends.
What is Evolus Inc’s EPS estimate?
Evolus Inc’s EPS estimate is 0.05.
How many shares outstanding does Evolus Inc have?
Evolus Inc has 64,819,786 shares outstanding.
What happened to Evolus Inc’s price movement after its last earnings report?
Evolus Inc reported an EPS of -$0.132 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went up 5.433%.
Which hedge fund is a major shareholder of Evolus Inc?
Currently, no hedge funds are holding shares in EOLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.25 (270.17% Upside)
$17.25 (270.17% Upside)
Blogger Sentiment
Bullish
EOLS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.62%
Trailing 12-Months
Company Description
Evolus Inc
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
EOLS Company Deck
EOLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth in consumer engagement, successful product launches, and international expansion, despite facing macroeconomic challenges and tariff uncertainties. Evolus demonstrates resilience and strategic adaptation, positioning for continued growth.View all EOLS earnings summariesEOLS Stock 12 Month Forecast
Average Price Target
$17.25
▲(270.17% Upside)
Technical Analysis
Emergent Biosolutions
―
Rockwell Med
―
Organogenesis Holdings
―
Aquestive Therapeutics
―
Journey Medical Corp
―
Ownership Overview
3.24% Insiders
8.85% Mutual Funds
0.44% Other Institutional Investors
76.41% Public Companies and
Individual Investors